

att act

OIPE COS

TECH CENTER 1600 2900

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Harrington, et al.

Application No.: 09/484,331

Filed: January 18, 2001

For: **COMPOSITIONS AND METHODS** 

FOR NON-TARGETED ACTIVATION

OF ENDOGENOUS GENES

Group Art Unit: 1632

Examiner: Shukla, R.

Attorney Docket No.: 0221-0003L

**BOX DD** 

Commissioner of Patents Washington, D.C. 20231

## FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of document AR26 is submitted herewith. The cite number is based on the last cite number in the Second Supplemental Information Disclosure Statement filed on February 8, 2001.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available

In re: Harrington, et al. Appln. No. 09/484,331

Page 2

to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. § 1.97(c), after a first Office Action on the merits and before a final Office Action or Notice of Allowance. Accordingly, under 37 C.F.R. § 1.97(c)(1), Applicants hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

In re: Harrington, et al. Appln. No. 09/484,331

Page 3

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

It is believed there is no fee required in the filing of this document. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0622, referencing Attorney Docket No. 0221-0003L.

Respectfully submitted,

SHANKS & HERBERT

AnnelSrow

Anne Brown

Reg. No. 36,463

Date: July 24, 2001

TransPotomac Plaza 1033 N. Fairfax Street Suite 306 Alexandria, VA 22314-1540